Molecular Design, Functional Characterization and Structural Basis of a Protein Inhibitor Against the HIV-1 Pathogenicity Factor Nef by Breuer, Sebastian et al.
Molecular Design, Functional Characterization and
Structural Basis of a Protein Inhibitor Against the HIV-1
Pathogenicity Factor Nef
Sebastian Breuer
1¤, Simone I. Schievink
2, Antje Schulte
1, Wulf Blankenfeldt




1Abteilung Physikalische Biochemie, Max-Planck-Institut fu ¨r molekulare Physiologie, Dortmund, Germany, 2Department fu ¨r Infektiologie, Virologie, Universita ¨tsklinikum
Heidelberg, Heidelberg, Germany
Abstract
Increased spread of HIV-1 and rapid emergence of drug resistance warrants development of novel antiviral strategies. Nef, a
critical viral pathogenicity factor that interacts with host cell factors but lacks enzymatic activity, is not targeted by current
antiviral measures. Here we inhibit Nef function by simultaneously blocking several highly conserved protein interaction
surfaces. This strategy, referred to as ‘‘wrapping Nef’’, is based on structure-function analyses that led to the identification of
four target sites: (i) SH3 domain interaction, (ii) interference with protein transport processes, (iii) CD4 binding and (iv)
targeting to lipid membranes. Screening combinations of Nef-interacting domains, we developed a series of small Nef
interacting proteins (NIs) composed of an SH3 domain optimized for binding to Nef, fused to a sequence motif of the CD4
cytoplasmic tail and combined with a prenylation signal for membrane association. NIs bind to Nef in the low nM affinity
range, associate with Nef in human cells and specifically interfere with key biological activities of Nef. Structure
determination of the Nef-inhibitor complex reveals the molecular basis for binding specificity. These results establish Nef-NI
interfaces as promising leads for the development of potent Nef inhibitors.
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Introduction
Highly active antiretroviral therapy (HAART) currently em-
ployed to treat AIDS patients consists of a combination of drugs
that target the HIV enzymes reverse transcriptase, protease and
integrase as well as inhibitors of virus entry. Although HAART is
highly effective, its high cost and limited availability in
underdeveloped areas severely limit the success of current anti-
HIV therapy. Moreover, the rapid emergence of drug resistance
mutants and the increased worldwide spread of such treatment
resistant HIV variants pose increasing problems to effective
treatment of HIV-patients [1]. One of many strategies to improve
this situation is the exploitation of additional drug targets that
could be added to the current regiment. Ideally, such targets
comprise viral factors, since interference with host cell factors often
compromises physiological function or even viability of host cells
[2].
The Nef protein is an accessory gene product of HIV and SIV
that is dispensable for virus spread in experimental ex vivo cell
culture systems [3]. In infected patients or monkeys however, Nef
is critical for high virus replication and disease progression. In fact,
defects in the nef gene lead to slowly progressing or even
asymptomatic infections and transgenic mice expressing Nef as
the only HIV-1 gene product develop AIDS-like disease [4–7].
Thus, Nef is an important factor for AIDS pathogenesis. Although
compounds interfering with Nef’s activity would thus be of obvious
global benefit, Nef is currently not a target of antiviral measures.
This lack of Nef targeting reflects the limited knowledge about the
mechanism by which Nef promotes virus spread and accelerates
disease progression in patients. Over the last years it has become
clear that Nef’s impact on AIDS pathogenesis results from the
combined action of several independent activities [8,9]. First, Nef
acts as a factor that prevents recognition of HIV infected cells by
the host immune system (immune evasion) via a reduction of the
cell surface density of bioactive MHC class I and II molecules [10]
and possibly by restriction target cell motility [11]. Second, Nef
alters the activation state of HIV target cells to increase their
permissivity to virus replication and prolongs their life span to
optimize virus production [9,12,13]. Third, Nef augments the
infectivity of HIV particles [14]. This effect is not potentiated over
several rounds of replication due to efficient but Nef-insensitive
cell-to-cell spread, however accounts for the slight delay in
replication kinetics observed for nef-deficient HIV-1 [15]. To
achieve this multitude of activities, Nef has evolved as versatile
adaptor for protein interactions that lacks intrinsic enzymatic
activity, which allows the viral protein to affect a wide range of
host cell protein sorting and signal transduction processes [3]. The
lack of enzymatic activity and of a well defined ex vivo assay system
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however, hampers the development of potent inhibitors that are
effective against a broad range of Nef functions. Thus, the
previously described Nef-interacting small compounds bind Nef
only with relatively low affinity, display high cytotoxicity and/or
interfere with only a subset of Nef interactions and functions [16–
19]. We therefore reasoned that a rational and structure-based
approach may be required for the development of an effective and
multifunctional Nef inhibitor.
The structure of HIV-1 Nef is characterized by its flexible loop
regions that together comprise more than half of the protein
sequence [20]. Nef contains an N-terminal myristoylation site
followed by an amphipathic helix for the association with cellular
membranes that is thought to be critical for all Nef activities. A
central PxxP motif for the interaction with SH3 domains is located
within a loop section that bridges the N-terminal anchor domain
to the structured core domain. This motif is essential for many
interactions of Nef with host cell signal transduction cascades as
well as for the downmodulation of cell surface receptors such as
MHC-I and CCR5 [21,22] and overexpression of isolated SH3
domains that bind to Nef with high affinity can interfere with its
activities [23]. A dileucine based endocytosis motif (ExxxLL) is
exposed at the tip of an approximately 30 residue encompassing
C-terminal flexible loop to mediate the interaction with protein
transport complexes, an interaction that mediates cell surface
removal of CD4 and enhancement of virion infectivity by Nef
[24,25]. The recognition site for the cytoplasmic tail sequence of
CD4 instead is supposed to reside within a hydrophobic groove on
the core domain structure of Nef [26].
The assembly of such diverse yet highly conserved interaction
motifs spread out in various flexible loop sections of the target
protein renders the generation of Nef specific inhibitors that
interfere with more than one individual Nef function at a time a
challenging task. We thus chose a strategy aimed at wrapping the
surface of Nef by the combination of different, physically linked,
target domains and the iterative optimization of domain
composition and linker segments.
Results
Molecular design of HIV-1 Nef interacting proteins
Nef is composed of a series of interaction motifs that spread over
the surface of the protein in flexible regions at diverse sites and
mediate specific interactions with host cell proteins (Figure 1A).
Nef mutagenesis studies established that only simultaneous
disruption of several independent protein interactions of Nef
efficiently abrogates the complex array of its biological activities
[8]. We therefore hypothesized that a Nef protein inhibitor has to
shield several of these interaction motifs at a time. In addition,
targeting multiple conserved regions simultaneously will limit the
ability of resistance development. Based on the currently available
knowledge about the structure-functional relationship in HIV-1
Nef, several candidate interaction motifs were considered
(Figure 1B). First, we selected the SH3 domain of Hck as lead
structure (referred to as ‘Nef-Interacting protein 1-1’ or ‘NI1-1’) to
target the central PxxPxR motif in the poly-proline rich loop of
Nef because of its relatively high affinity binding to Nef [27].
Variations of six residues in the so-called RT-loop in between the
first and second b-strand of the SH3 domain further increase the
affinity to Nef by 20- to 30-fold [28]. Besides human wild type
Hck-SH3 (78–138) that contained the sequence E90AIHHE within
the RT-loop, we therefore also generated the two mutant SH3
domains V90SWSPD and Y90SPFSW, termed NI1-2 and NI1-3,
respectively.
Second, we included a helical region in the b-subunit of the
adaptor protein complex 2 (AP-2) that was supposed to act as
binding site for dileucine based sorting motifs [29]. Constructs
encompassing aa 279–510 or 352–521, corresponding to either
eight or six HEAT repeats of the domain structure, respectively,
were generated (series NI2). Third, we used the cytoplasmic tail
sequence of CD4 itself to interact with its recognition site on Nef.
Two different lengths of this peptide (37 or 23 residues) were
employed either as wild type sequence or in conjunction with
mutation of an Lck-binding motif CQC to SQS, or mutation of
the dileucine based internalization motif LL to AA (series NI3). As
alternative approach to target the dileucine internalization motif in
Nef, the VHS domain of the human GGA2 protein (residues 21–
164) was used that was shown to bind acidic-cluster-dileucine
sorting signals of the mannose-6-phosphate receptor [30,31].
Finally, for those constructs that drive NI expression in human
cells, we added a lipidation signal either as N-terminal myristoyla-
tion motif (MGxxxS) or as C-terminal farnesylation motif (CVLS)
to the protein, sometimes in combination with additional
palmitoylation sites, for the targeting to cellular membranes.
Likewise, an HA-epitope was added always at the alternate site of
lipidation in the cellular expression constructs for antibody
recognition.
The selected sequences were fused in various combinations
using different linker length and variable domain successions to
result in four different generations of putative Nef-interacting
molecules (Figure 1C). These fusion proteins were designed to
interact simultaneously with multiple binding sites of Nef, leading
thus to increased affinity and specificity for the viral protein. In
total 23 different constructs were designed and expressed for in vitro
studies to characterize their binding affinities to Nef and another
25 constructs for studies in human cells. An overview of the
constructs generated is shown in Figure S1.
Binding specificity between Nef and inhibitor proteins
We first purified the recombinant NI proteins (Figure 1D) and
analyzed their binding capacities to HIV-1 Nef in vitro. Binding
affinities of the direct interactions were determined by isothermal
titration calorimetry (ITC), surface plasmon resonance (SPR) or
fluorescence spectroscopy to compare the dissociation constants of
the various fusion proteins. Nef (D1-44) bound to the wild type
Hck-SH3 domain (termed ‘NI1-1’) with a Kd value of 1.54 mMi n
agreement with previous studies [32]. Mutation of the RT-loop
sequence E88AIHHE to VSWSPD (‘NI1-2’) or YSPFSW (‘NI1-3’)
led to an increase of the Nef binding affinity to 179 nM or even
48 nM, respectively, indicating the enormous contribution of this
region to the PxxPxR recognition of the SH3 domain (Figure 2A
and Table 1). To preserve the experimental range of interaction
for further improvements we used in the following the VSWSPD
sequence in the SH3 domain as a lead structure in the next
generations of fusion proteins.
Fusion of the proposed dileucine binding domains to the SH3
domain (generations NI2 and NI4) resulted in protein products
that tended to precipitate upon purification in vitro. Likewise, these
constructs were unstable when expressed in mammalian cells (data
not shown) and could therefore not be investigated further.
Attachment of the cytoplasmic domain of CD4, however, which is
the smallest unit tested, turned out to be suitable for in vitro
characterization and amenable for structure-function based
binding improvements. N-terminal fusion of CD4 to SH3 by a
five residue linker resulted in a dissociation constant of 84 nM of
the 103 residue encompassing protein (NI3-1) and shortening of
the CD4 segment to 23 residues similarly resulted in a Kd of
107 nM (NI3-8). Importantly, mutation of two cysteines (CQC to
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intermolecular zinc finger with Lck [33] did not affect the binding
affinity to Nef (Kd=84 nM and 88 nM, respectively; compare
NI3-1 and NI3-3). In contrast, mutation of the dileucine motif in
CD4 to alanine (NI3-4) largely diminished the binding affinity to
Nef (544 nM), indicating the requirement of these residues for the
interaction. The best binding affinity was indeed observed for the
wild type CD4 sequence attached with a glycine-serine-rich linker
of 12 residues to the SH3 domain (Kd=64 nM; construct NI3-5,
Table 1).
This observation prompted us to swap the two domains which
led to the generation of constructs NI3-9 to NI3-14. Indeed, an
improved dissociation constant of 26 nM was determined by ITC
for the interaction of a SH3-CD4 fusion protein (NI3-9) with Nef,
which is the tightest interaction described for a molecule with Nef
to date. Mutation of the two cysteines caused again no effect (NI3-
10), while mutation of the dileucines resulted in a four-fold
decrease of affinity (NI3-11). Consistently, truncation to a fusion
protein that lacks the cysteine residues, encompassing 92 residues
only (NI3-13), showed still a binding affinity of 41 nM. The C-
terminal residues of the CD4 segment did therefore not
significantly contribute to the binary interaction. We next tested
the binding of these improved proteins to a Nef mutant in which
the PxxPxR motif was replaced by AxxAxA, which typically
abrogates the interaction to SH3 domains. Now, the interaction
with NI3-9 showed still a Kd of 1.17 mM (Figure 2C), which might
be regarded as the contribution of the dileucine motif in CD4 to
the binding affinity to Nef.
Finally, we tested the effect of the N-terminal flexible membrane
anchor domain of Nef to the binding of the SH3-CD4 fusion
proteins (Figure 2B). While for the full length Nef protein a
dissociation constant to NI3-13 of 41 nM was determined, its
successive truncation as D1-27, D1-44 and D1-58 resulted in
decreased binding affinities of 51 nM, 96 nM and 149 nM,
respectively. The relative change in binding affinity observed was
thus largest between starting positions 28 and 45, while deletion of
the N-terminal 27 residues only marginally affected the interac-
tion. This observation is in line with the assumption that the far N-
terminal region is embedded in the lipid bilayer where it may form
an amphipathic helix to sustain membrane binding [34], while
residues outside the core domain of Nef could still contribute to the
interaction with CD4.
The tight interactions between Nef and its inhibitory proteins
were confirmed by equilibrium fluorescence titration measure-
ments using the dansyl labeled SH3-CD4 fusion variant NI3-3,
that contained only one cysteine for labeling, with increasing
concentrations of wild type full length Nef (Figure S2). Similarly,
surface plasmon resonance was used to determine the dissociation
constant between His-tagged CD4-SH3 (NI3-9) and four different
concentrations of Nef that revealed a Kd of 28 nM (Figure S3).
Both techniques yielded dissociation constants that were in
agreement with the ITC measurements. Finally, size exclusion
chromatography was performed to address whether the increase in
Nef binding contributed by the CD4 segment was achieved in the
same molecule in cis or if it would be due to complex dimerization
or oligomerization in trans. Addition of the 11.5 kDa SH3-CD4
fusion NI3-3 to the 25 kDa Nef protein resulted indeed in a sharp
elution profile at 10.5 ml, corresponding to a molecular weight of
36 kDa for the monomeric complex (Figure S4). Moreover, the
content of aggregated Nef oligomers that eluted in the void volume
completely vanished upon addition of the Nef inhibitor NI3-9,
suggesting its tight binding and solubilization effect.
Cellular localization of Nef interacting proteins
We next addressed whether these NIs also associate with the
viral protein when expressed in cells. Based on the above in vitro
analysis and their small size we focused on the 3
rd generation of
NIs. All constructs NI3-1 to NI3-14 resulted in the expression of
stable proteins to comparable levels in 293T cells (Figure S5).
Expression of these NIs, either alone or in combination with Nef,
did not result in apparent cytotoxicity. Confocal microscopy
revealed that, when expressed alone or together with a GFP
control, most NIs displayed a predominantly diffuse cytoplasmic
subcellular distribution with some localization to the plasma
membrane (Figure S5A). NI3-7, NI3-9 and NI3-11, however,
localized prominently to intracellular membrane structures. Co-
expression of Nef.GFP with the NIs resulted in marked
colocalization of both proteins in most cases. This was most
pronounced for constructs NI3-1, NI3-7 and NI3-9 (Figure 3A)
that were subjected to further in depth analysis. Notably, the
localization of Nef.GFP was altered in the presence of these
constructs: while located at the plasma membrane, the cytoplasm,
as well as associated with cytoplasmatic membrane vesicles when
expressed alone, Nef.GFP was enriched at the plasma membrane
in the presence of NI3-1 and at intracellular vesicles upon co-
expression with NI3-7 and NI3-9. Most importantly and
irrespective of the specific subcelluar localization, high degrees of
colocalization were observed between the NIs and Nef.GFP (see
arrows). Consistently, Nef.GFP was found to physically associate
with NI3-1 and NI3-7 by co-immunoprecipation analysis
(Figure 3B). Together these results indicate that Nef associates
with the NIs in intact human cells.
NIs interfere with biological activities of Nef
To address whether the association of NIs affects the biological
properties of Nef, a series of functional assays was performed in the
absence or presence of NI3-1, NI3-7 and NI3-9. The ability of
Nef.GFP to reduce cell surface presentation of the receptor
molecules CD4, CCR5, MHC-I and CD71 was evaluated by flow
cytometry (Figure 4A). While CD71 was included as a Nef-
insensitive negative control, downregulation of cell surface CD4,
MHC-I and CCR5 receptors are established Nef activities that
depend on select motifs in Nef: Nef-mediated downregulation of
CD4 requires endocytic motifs in the C-terminal flexible loop of
Nef as well as an interaction with the cytoplasmic tail of CD4 [3].
In contrast, effects of Nef on MHC-I and CCR5 are flexible loop
independent but require several interaction motifs in the Nef core
domain [21,22]. Expression of the NIs alone had no significant
effect on cell surface levels of CD4, CCR5, MHC-I or CD71 at
these levels of expression. In contrast, Nef significantly decreased
cell surface exposure of CD4, CCR5 and MHC-I but not of the
negative control CD71. These effects were inhibited with variable
Figure 1. Schematic display of Nef Interacting (NI) protein design. (A) Cartoon of interaction motifs within the Nef structure. (B) Protein
domains and lipidation signal sequences employed for the design of Nef interacting proteins. The number of different constructs generated and the
proposed target sites are shown to the right. (C) Fusion design of four different NI generations. Different recognition domains were assembled in
alternating orders and combined with various membrane association motifs to result in different expression constructs, used either for recombinant
protein production or in vivo cell expression. (D) Display of the three high affinity binders designed to wrap the interaction surfaces of Nef. (E) SDS
PAGE display of selected recombinant Nef and NI proteins used for in vitro binding analyses.
doi:10.1371/journal.pone.0020033.g001
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CD4 and MHC-I downmodulation by Nef, while NI3-7 displayed
only partial inhibition of Nef-mediated CD4 downregulation. All
three inhibitors had intermediate effects on CCR5 downmodula-
tion by Nef. Of note, cross-talk of inhibitors NI3-7 and NI3-9 with
the fluorescent channel used for the flow cytometric analysis of
MHC-I and CD71, respectively, precluded measurements of these
two receptors.
Additionally, we examined the ability of the NIs to interfere
with the enhancement of virion infectivity by Nef. This activity is
exerted by Nef during virus particle production via a complex
array of molecular determinants [8]. HIV-1 wt or Nef-deficient
HIV-1 (HIV-1Dnef) particles were produced in the absence or
presence of NI3-1, NI3-7 or NI3-9 and the infectivity of the
produced viruses was titrated on TZM indicator cells in a single
round infection assay. As expected [8,35], wt HIV-1 was approx.
5-fold more infectious than HIV-1Dnef when produced in the
absence of the NIs (Figure 4B). Importantly, co-expression of each
of the three NIs significantly reduced the infectivity of the
produced particles. No effect of the NIs was detected on the
amount of particle release (data not shown) and the infectivity of
HIV-1Dnef was unaffected by the NIs. Thus, NI expression
specifically blocked the positive effect exerted by Nef on virion
infectivity during virus production. The fact that NI3-7 blocks
enhancement of virion infectivity despite having little effect on
CD4 downregulation induced by the viral protein indicates that,
even though well correlated genetically, reduction of CD4 cell
surface density may not be sufficient to explain Nef’s effects on
virion infectivity. Together, these results establish that NI3-1 and
NI3-9 efficiently inhibit downmodulation of cell surface CD4 and
MHC-I molecules as well as enhancement of virion infectivity
mediated by HIV-1 Nef in human cells.
Structure of Nef with its inhibitory proteins
To explore the structural basis of the inhibition of Nef activity
by NIs we determined the crystal structures of Nef in complex with
NI1-2 and NI3-13. Crystals of NefSF2 (45-210, D158-178) bound
to NI1-2 domain were refined to 2.0 A ˚ resolution (Table 2). They
contained two Nef–NI1-2 complexes in the asymmetric unit of
which the first one (chains A and B) was better defined by its
crystallographic electron density and is discussed in the following.
The C-terminal flexible loop of Nef that contained the endocytic
dileucine motif was partly truncated in the crystallized complex,
nonetheless no electron density was observed starting from
residues 155 to 179, in line with the assumption of a flexible loop
section (Figure 5A).
Interactions between the PxxP motif of NefSF2 and the
corresponding tryptophan-tyrosine based recognition surface on
the Hck-SH3 domain of NI2-1 were mediated similarly as
observed for NL4-3 Nef(T71R) to FynSH3(R96I) and LAI Nef to
FynSH3 [36,37]. In addition, two long antiparallel helices a4 and
a5 (residues Y85-K98 and Q108–Q122) of Nef form a
Figure 2. Isothermal titration calorimetric measurements between Nef and selected Nef interacting proteins. (A) Binding analyses
between Nef and optimized GST-Hck-CD4 chimeras. Displayed are ITC measurements with NI1-1 (Hck, upper left), NI1-2 (Hck-RT loop optimized;
upper-right), NI3-1 (CD4-Hck; lower left) and NI3-9 (Hck-CD4; lower right). (B) Contribution of the length of the N-terminal membrane anchor domain
of Nef to the binding to NI3-13. (C) Binding between the prototypic Nef inhibitor NI3-9 (HckSH3-polyGly-CD4) and the SH3 domain binding defective
Nef (PxxPxR to AxxAxA) mutant. The dissociation constant of 1.2 mM revealed the putative contribution of the dileucine motif of CD4 to the Nef
interaction. The thermodynamic parameters and the dissociation constants of the interactions are listed in Table 1.
doi:10.1371/journal.pone.0020033.g002




(6C) DG (kcal/mol) DH (kcal/mol) TDS (kcal/mol) molar ratio Kd (nM)
Nef (D1-44)/NI1-1 25 27.93 24.5060.09 3.43 0.97 15376195
Nef (D1-44)/NI1-2 25 29.20 28.1660.07 1.04 0.99 179629
Nef (D1-44)/NI1-3 25 29.98 27.9960.07 2.00 0.95 48611
Nef (wt)/NI1-1* 15 28.71 24.2460.03 4.47 1.08 249627
Nef (wt)/NI1-2* 15 29.04 28.9060.02 0.138 1.07 14066.7
Nef (wt)/NI3-1* 15 29.33 28.5160.03 0.82 1.09 8467.1
Nef (wt)/NI3-8* 15 29.19 28.2060.04 0.99 0.93 107610.6
Nef (wt)/NI3-5* 15 29.49 28.2260.04 1.27 1.06 6467.5
Nef (wt)/NI3-3* 15 29.30 28.6460.02 0.66 1.12 8865.4
Nef (wt)/NI3-4* 15 28.26 28.5560.07 20.288 0.97 544659
Nef (wt)/NI3-9* 15 210.01 211.4060.03 21.39 0.97 2662.1
Nef (wt)/NI3-13* 15 29.74 27.0460.03 2.70 0.98 4164.4
Nef (wt)/NI3-10* 15 29.98 211.5060.03 21.52 1.03 2761.8
Nef (wt)/NI3-11* 15 29.25 26.9160.02 2.35 1.10 9765.0
Nef (AxxA)/NI3-9* 25 28.09 24.1060.05 4.00 0.85 11736111
Nef (D1-27)/NI3-13* 15 29.61 212.2260.10 22.61 1.00 5169.8
Nef (D1-44)/NI3-13* 15 29.26 216.1360.13 26.87 1.06 96615
Nef (D1-58)/NI3-13* 25 29.31 213.8160.18 24.50 0.98 149627
*These samples were used as GST-fusion proteins.
doi:10.1371/journal.pone.0020033.t001
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bering of secondary structure elements is based on the assembly of
a full length Nef structure composed of the N-terminal anchor and
the C-terminal core domain [20]. The accessible surface of helices
a4 and a5 is separated into two parts by the highly conserved
residues F94 and W117, whose aromatic side chains oppose each
other and act as gatekeepers to form a barrier in the helical region
(Figure 5B). The mutant residues V90SWSPD of the Hck RT loop
undergo tight interactions with the proximal region of these
antiparallel helices, with tryptophan 92 of Hck contributing itself
to the high binding affinity with 41 interactions to six different
residues of Nef within a shell of 4 A ˚. Many of these interactions
were mediated by stacking of the aromatic side chains W92Hck to
F94Nef, as well as facing interactions to W117Nef. In addition,
R81Nef in the PxxPxR motif of Nef showed direct ionic
interactions to D96 of Hck and the side chain of Q122Nef made
Figure 3. Association of Nef with NIs in human cells. (A) Localization of Nef and NIs in HeLa cells. GFP or Nef.GFP was co-expressed with an
empty control vector or the indicated NIs and subjected to confocal microscopy analysis following fixation and anti-HA immunostaining. Presented
are confocal sections of the middle of representative cells. Scale bar=10 mm. Arrows indicate examples of colocalization between Nef.GFP and NIs. (B)
Co-immunprecipitation of Nef.GFP and the indicated NIs from HeLa cells. Shown is a Western blot analysis of Nef.GFP and NIs in the input cell lysate
(upper panel) and following anti-GFP immunoprecipitation (lower panel).
doi:10.1371/journal.pone.0020033.g003
Molecular Inhibitor of HIV-1 Nef
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20033Molecular Inhibitor of HIV-1 Nef
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20033tight interactions to the hydroxyl group of Y89Hck (2.6 A ˚) and the
main chain oxygen of V90Hck (2.9 A ˚). Likewise, the hydroxyl
group of S93Hck was hydrogen bonded to D90Nef (2.6 A ˚) and
D95Hck formed an ionic interaction to K86 of Nef (Figure S6A,B).
While the tight interactions that account for the increased
affinity of mutant Hck NI1-2 compared to wild type Hck occurred
all at the hydrophobic site of the two helices in Nef proximal to the
PxxP motif, we now observed a previously unresolved additional
helix at the N-terminus of the core domain of Nef (Figure 5B). This
helix, ranging from residue A60 to E69, bound at the distal site of
the two countercurrent helices with W61 of Nef interacting with
hydrophobic residues L104 on the short b1 strand of Nef, I113,
L114 and the methylene groups of R110 (Figure S6C). In the
NMR structure of NefBH10 this tryptophan residue was previously
reported to exist in two different conformations with one
conformation attached to its core domain structure [26]
(Figure 5C). Of note, the acidic cluster motif of four successive
glutamates (E66–E69), that was reported to interact with the
sorting adaptor protein PACS1 [38], adopts a helical conforma-
tion on this structure element.
The CD4 moiety interacts with the core domain structure
of Nef
Crystals of Nef (45-210, D158-178) in complex with NI3-13
were grown under similar conditions but despite extensive testing
by seeding, dehydration and additives, these crystals diffracted
only to 3.5 A ˚ resolution. Unfortunately, there was no electron
density visible that would unambiguously account for the CD4
part of the inhibitory molecule. However, the resolution achieved
was sufficient to show that the N-terminal chain of Nef in one
complex of the asymmetric unit was bended away such that the
binding site distal to the PxxP motif on face the F94–W117
gatekeeper residues could become accessible for other interactions.
We therefore performed NMR spectroscopy measurements of
15N
labeled Nef (45-210) in complex with either NI1-2 or NI3-13 as
HSQC mapping experiments. The full
15N/
1H HSQC overlay
spectra of Nef and the Nef–NI3-13 complex are shown in Figure
S7. As can be clearly seen from the tryptophan HNe region of the
spectra, W61 existed in two almost equally populated conforma-
tions in the Nef protein alone but also when bound to the SH3
domain (Figure 5D, left panel, blue and red peaks). In contrast,
when bound to the SH3-CD4 inhibitor construct NI3-13, W61 of
Nef was fully shifted toward the low field state that was previously
assigned with the open conformation of the W61 equilibrium
(Figure 5D, right panel, red line) [26]. We therefore conclude that
the NI3-13 molecule not only binds to the PxxPxR motif of Nef,
but also interacts with the RT loop recognition site on Nef by its
improved loop mutants, namely W92. In addition, NI3-13
contributes with its dileucine based sorting motif to the binding
of Nef at a hydrophobic surface patch distal to the gatekeeper
residues F94 and W117. Thus, NI3-13 interacts with Nef at three
different but highly conserved sites leading to a substantial
wrapping of the interaction surfaces of the viral protein.
Discussion
In this study we engineered a 10.0 kDa protein (86 amino acids)
that binds to HIV-1 Nef in the low nano-molar range. This
protein, NI3-13, targets three highly conserved sites in Nef,
namely the PxxPxR loop, the RT loop recognition site on Nef and
the binding site for the CD4 dileucine based sorting signals on Nef.
For tissue culture experiments the inhibitor protein was addition-
ally targeted to lipid membranes by a myristoylation/palmitoyla-
tion motif, which is thought to further increase the binding
specificity to membrane-localized Nef. Thus, a protein construct
was designed that simultaneously covered three interaction sites of
Figure 4. Inhibition of Nef functions by NIs in human cells. (A) FACS analysis of receptor cell surface density. Depicted are the cell surface
levels of the indicated receptors on CHO) hCD4hCCR5 (for CD4 and CCR5) or HeLa-derived TZM (MHC-I, CD71) cells expressing GFP or Nef.GFP
together with an empty control plasmid or the indicated NIs. Values are mean +/2 STD from triplicate experiments relative to the GFP control sample
that was arbitrarily set to 100%. (B) Single round of replication analysis on TZM cells for determination of virion infectivity. 2 ng p24 of HIV-1 wt or
DNef virions produced in the presence of an empty control plasmid or the indicated NIs were used to infect TZM reporter cells. 36 h post-infection,
cells were fixed, stained for b-galactosidase, and the number of blue cells was counted. Data represent mean values +/2 STD from triplicate
experiments plotted relative to the HIV-1 wt control that was arbitrarily set to 100% (corresponding to 200–300 blue cells/96 well). Asterisks indicate
statistical significance as calculated by students t-test (***, p,0.0005; **,p,0.005; *, p,0.05; n.s., non significant). Statistical significance was
evaluated between the corresponding GFP and Nef.GFP (A) or HIV-1 wt and DNef samples, respectively.
doi:10.1371/journal.pone.0020033.g004








Space group P41212P 6 1
Cell dimensions
a, b, c (A ˚) 65.69, 65.69, 279.07 112.46, 112.46, 130.03
a, b, c (u) 90, 90, 90 90, 90, 120
Wavelength 0.9 0.9763
Resolution (A ˚)
2 50 – 2.0 (2.1 – 2.0) 20 – 3.45 (3.55 – 3.45)
Rmerge 5.2 (27.5) 6.6 (30.5)
I/s (I) 18.2 (4.4) 16.6 (3.9)
Completeness (%) 100 (100) 99.9 (100)
Redundancy 26.6 (23.4) 12.6 (12.8)
Refinement
Resolution (A ˚) 50 – 2.0 (2.05 – 2.0) 20 – 3.45 (3.71 – 3.45)
No. reflections 40486 (3095) 12282 (2442)
Rwork 16.8 (20.0) 21.6 (28.0)








Bond lengths (A ˚) 0.026 0.016
Bond angles (u) 1.823 1.584
PDB entry code 3REA 3REB
1All data sets were collected from one single crystal.
2Values in parentheses refer to the highest resolution shell.
doi:10.1371/journal.pone.0020033.t002
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non-functional.
The simultaneous targeting of multiple interaction sites is a well
proven approach to generate high affinity and specificity binding
to a protein of interest [39,40]. Indeed, we show here that the
binding affinity of a designed protein inhibitor to HIV-1 Nef is
increased from 250 to 26 nM by fusion of two structural elements
and further lead optimization. This fusion protein is the tightest
binder to Nef known to date and supposedly covers a large surface
on the target protein. The selection of target sites within Nef was
strictly dependent on high sequence conservation in HIV-1 Nef
alleles of different subtypes and stages of disease. The ability to
interact with the cytoplasmic tail sequence of CD4 at the plasma
membrane is potentially the most conserved feature of Nef and an
ancestral function in the evolution of this protein in HIV/SIV
lentiviruses [11,41]. The binding of the central PxxP motif to
cellular SH3 domains adds to the diversity of Nef function in
signaling and trafficking aspects. The SH3 RT loop is known to
interact with a unique hydrophobic groove on Nef that
significantly contributes to the specificity of the viral protein in
SH3 domain recognition [27,28]. Targeting of the inhibitor
protein to cellular membranes by lipidation signals finally, further
relates to the highly conserved presence of an N-terminal
myristoylation signal in Nef and reduces the interaction space to
a two dimensional layer.
Our functional studies in human cells provide proof-of-concept
for potent inhibition of Nef function by the prototype HIV-1 Nef
protein inhibitor. Importantly, this included inhibition of mech-
anistically independent activities such as down modulation of cell
surface CD4 and MHC-I molecules, confirming the successful
simultaneous interference with independent protein interactions of
Nef in the absence of detectable cytotoxicity. Furthermore,
inhibition of Nef was also achieved in the context of infectious
HIV-1, where positive effects of Nef on the infectivity of viral
progeny were blunted by the presence of the protein inhibitor.
These results warrant the development of future generations of
such prototype inhibitors. However, therapeutic exploitation of
anti-infectives based on intracellular expression of protein
inhibitors are hampered by difficulties including delivery as well
as inhibitor stability and immunogenicity [42]. Similar to the
recently generated inhibitors of interactions between HIV-1
integrase and its cellular cofactor LEDGF/p75 [43], such
developments will build on the complex structure described here
to rationally design small and cell-permeable Nef-interacting
compounds. Their future functional characterization will focus on
the full array of Nef activities, including analyses in primary
human cells in the context of viral infection. Since one limitation
of these analyses consists of the lack of potent effects of Nef on
virus replication in ex vivo cell culture systems, ultimate validation
of Nef inhibitors will require investigations in in vivo models such as
humanized mice or HIV-1 susceptible transgenic rats [44–46].
Irrespective of its potential future clinical application, motif-
specific intracellular Nef inhibitors at present represent valuable
tools for studies of host cell interactions of the viral pathogencity
factor.
The structures of Nef–NI1-2 and Nef–NI3-13 complexes
described here reveal details of two conserved non-polar grooves
in the HIV-1 Nef protein that are potential target sites for
therapeutic intervention. Both sites are located on helices a4 and
a5 of Nef that are spread apart by gatekeeper residues F94 and
W117. While the site proximal to the PxxP motif harbors the
central residues of the RT loop, the distal site covers a newly
identified N-terminal helix of Nef (residues 60 to 69) with W61
mediating multiple interactions to hydrophobic residues L104,
I113 and L114. The 8-fold increase in affinity of the Hck-SH3
RT-loop mutant VSWSPD compared to the EAIHHE wild type
sequence is largely due to multiple interactions mediated by the
central tryptophane residue. Importantly, this Trp residue
captures the position of the mutant R96I in human Fyn kinase,
which was found to be a prerequisite and key site for the
interaction between the SH3Fyn domain and NL4-3 Nef [27,36].
The CD4 fragment of NI3-13 is unfortunately not resolved in the
low resolution crystal structure of its complex with Nef. However,
NMR spectroscopic analysis strongly support the displacement of
the before mentioned newly identified N-terminal helix by the
CD4 segment. Mutagenesis analyses showed that the CD4
dileucine motif is required for binding to Nef, while a C-terminal
cysteine-rich motif, which was shown to form an intermolecular
zinc-finger with the unique domain of Hck [33], did not contribute
to the interaction. This suggested that the C-terminal residues of
the CD4 segment did not contribute to the binary interaction
significantly and its truncation to a fusion protein that encom-
passed 86 residues only (NI3-13) showed still a binding affinity of
41 nM. Together, these interaction data prove indeed the two
hydrophobic cavities of Nef as potent pharmacophore target sites.
The design of protein inhibitors is often based on substrate
modifications (as e.g. histone deacetylase inhibitors, farnesyl
transferase inhibitors) or modifications of a co-enzyme/co-
substrate (as e.g. ATP analogues for kinases) that block an
enzymatic reaction. As such, inhibitors against reverse transcrip-
tase, protease and integrase that constitute current HAART
treatment target the active center of these enzymes. Combinations
of these drugs are known to be highly effective, however, escape
mutants that develop with time require constant monitoring and
adjustment of the drug regime [2]. Other classes of inhibitors are
fusion and attachment inhibitors against gp41 or CCR5 as well as
maturation inhibitors targeting Gag that both impair structural
factors of HIV. Fusion inhibitors have been designed in various
fashions, ranging from 20 to 44 amino acid long D-peptides which
interact with the tripartite coiled coil section of the glycoprotein,
blocking fusion and thus entry of the virus to the target cell
[47,48]. Finally, lead inhibitory molecules that target the HIV-1
capsid and prevent assembly of infectious virus particles have been
identified and are currently being developed towards therapeutic
application by a design approach to achieve cell penetration [49–
52]. While current anti-HIV infectives target enzymes or structural
proteins essential to viral replication, Nef might be regarded as an
accessory adaptor protein that fulfills many functions by an
assembly of multiple sequence motifs. The structural and
functional insight gained by the ‘‘wrapping Nef’’ approach
described here provide valuable lead information and proof-of-
Figure 5. Structure of the Nef–NI1-2 inhibitor complex. (A) Ribbon display of NefSF2 (44-210, D158-178) in complex with SH3Hck(VSWSPD) (NI1-
2). Residues in the complex interface are highlighted. Stacking interactions between F94Nef and W92Hck are shown. (B) Surface display of the NefSF2
core domain structure with the RT-loop sequence of Hck (top) and the newly identified helix a3 (bottom) of Nef shown as ribbon display. The gate
keeper residues F94 and W117 of Nef separate two hydrophobic patches in the assembly of the a4-a5 helices that are covered by mutant W92 of Hck
and W61 of Nef. (C) Superimposition of the N-terminal regions from the crystal structure determined here and the NMR structure of Nef [61]. (D) NMR
mapping experiments revealed displacement of the tryptophane 61 residue by the CD4 part of NI3-13. Shown is a titration series of NI1-2 (left) or NI3-
13 (right) to
15N-labeled Nef. Only the spectral region encompassing the HNe resonance signal of tryptophanes is shown.
doi:10.1371/journal.pone.0020033.g005
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potent and clinically applicable Nef inhibitors. Future work will
match with the design, functional characterization and structure
determination on Nef protein inhibitors provided in this study.
Materials and Methods
Cloning, expression and purification of Nef inhibitor
constructs
HIV-1 NefSF2 proteins (GenBank accession number K02007)
were expressed in E.coli BL21(DE3) cells from a codon optimized
plasmid with a TEV protease cleavable N-terminal His6-tag using
pProEx HTa (Stratagene) as expression vector or pET-23d
(Novagen) with a C-terminal His6-tag. The expression and
purification of wild type Nef or N-terminally truncated Nef (D1-
27), Nef (D1-44), Nef (D1-58), and mutant Nef (P76A, P79A, R81A)
all in combination with a C-terminal cysteine to alanine mutation
(C210A) was performed similarly as described [53]. Briefly, bacterial
cells were cultured in LB medium containing 100 mg/ml ampicillin
at 30uC and induced at OD600=0.8 with 0.5mM IPTG for
additional 5 hrs. For NMR experiments Nef (D1-44) has been
cultured in presence of minimal medium containing 1 g/l
15NH4Cl.
The harvested cells were resuspended in20 mMTris/HCl (pH 8.0),
500 mM NaCl, 5 mM ß-mercaptoethanol, 1 mM PMSF, lysed by
fluidizer and cleared by spinning for 45 min at 30,000 g. The fusion
proteins were separated from the bacterial proteins by affinity
chromatography using Ni-NTA resin (Qiagen) and size exclusion
chromatography on a Superdex 75 column (Amersham Bioscience),
analyzed by SDS Page and MALDI-TOF mass spectrometry and
stored in 10 mM Tris/HCl (pH 8.0), 50 mM NaCl at 280uC.
Fusion constructs of human Hck-SH3 domains (AC: M16591)
with either the adaptor protein b2 subunit (M34175), the
cytoplasmatic tail of human CD4 (M12807) or the VHS domain
of GGA2 (AF233522), were generated by PCR using a cassette
system of restrictions sites with NcoI and EcoR1 at the 59 and 39
end, respectively, and BamHI or SpeI in between the domains.
Typically, a glycine rich amino acid linker as GGGTSGGG or
GGGTSGGGSGGG was cloned in between the domains. For in
vitro experiments, proteins were expressed with an N-terminal
glutathione S-transferase (GST-) tag using the pGEX-4T1 Tev
vector system (Amersham Bioscience) in LB medium containing
100 mg/ml ampicillin at 30uC and induced at an OD600 nm=0.8
with 0.5 mM IPTG for additional 8 h. The harvested cells were
resuspended in 20 mM Tris/HCl, pH 8.0, 500 mM NaCl, 2 mM
GSH, 1 mM EDTA, 0.5 mM DTE and 1 mM PMSF, lysed by
fluidizer and cleared by spinning for 45 min at 30,000 g. By
affinity chromatography utilizing GSH resin (Amersham Biosci-
ence) and size exclusion chromatography on a Superdex 75
column (Amersham Bioscience) the fusion proteins were separated
from the bacterial proteins, analyzed by SDS Page and MALDI-
TOF mass spectrometry and stored in 10 mM Tris/HCl, pH 8.0,
50 mM NaCl at 280uC.
For cellular expression assays, Nef interacting proteins were
optionally targeted to lipid membranes by an N-terminal
myristoylation signal MGSRWSK, often in combination with a
palmitoylation motif (S3C), since myristoylation alone was often
shown to be not sufficient for stable membrane association [34,54].
Alternatively, a C-terminal palmitoylation and farnesylation
sequence KLRKLNPPDESGPGCMSCKCVLS was added that
was adopted from human H-Ras.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments were
performed in ITC buffer (10 mM Tris/HCL, pH 8.0, 100 mM
NaCl) at 15 or 25uC using a Microcal VP-ITC apparatus
(MicroCal, Northampton, MA), similarly as described [55]. Prior
to the titration experiments, Nef and inhibitor proteins were
equilibrated in ITC buffer by dialysis or resuspension and
exhaustively degassed. For all reactions a solution of 400 to
500 mM inhibitor protein was injected in 25–40 steps of 4 or 8 ml
volume to a solution of 40 to 50 mM Nef protein placed in the
measurement cell. Each titration experiment was corrected by a
control titration of the ligand into ITC buffer. Experimental data
were fitted using the nonlinear least-squares algorithm with
ORIGIN software (MicroCal).
Surface plasmon resonance
Glutathione S-Transferase tagged inhibitor protein NI3-9 at
0.4 mg/ml concentration was immobilized on the surface of a
SPR-based biosensor CM5 chip (BIAcore AB, Sweden) via an
anti-GST antibody (BIAcore AB, Sweden) to record binding to
Nef in real time. The binding experiments were performed using a
SPR-based biosensor (BIAcore 1000, BIAcore AB, Sweden) in
SPR buffer (10 mM HEPES pH 8.0, 150 mM NaCl, 0.005%
IGEPAL) at 25uC. The association of a dilution series of hexa-
histidine tagged Nef (400–1000 nM) was monitored over time at a
flow rate of 5 ml/min for 380 s. Dissociation was analyzed by
washing with 1 M guanidine hydrochlorid buffer for 240 min.
Rate constants were calculated by using the evaluation software
supplied by the manufacturer.
Size exclusion chromatography
Analytical gel filtration of Nef and the complex of Nef and NI3-
3 was performed using an HPLC (Waters) system and a Superdex
S75 (10/30) column (Amersham Biosciences). 100 ml of 1 mg/ml
protein solution was loaded with an elution volume of 1 ml per
minute in 20 mM Tris/HCL (pH 8.0), 50 mM NaCl onto the S75
column at room temperature. The optical density was monitored
at a wavelength of 280 nm over the time course of the experiment.
Complex crystallization and structure determination
For crystallization 15 mg ml
21 of purified Nef–NI1-2 protein
complex was stored in 30 mM Hepes buffer, pH 8.0, and 50 mM
NaCl. Crystallization drops were set at a 1:1 ratio with the
reservoir solution containing 10% (w/v) PEG 8000, 0.2 M MgCl2,
15 mM MnCl2, 5% (v/v) ethylene glycol, 100 mM Tris buffer,
pH 7.0, and subjected to hanging drop vapor diffusion at 12uC.
Crystals appeared within three days and grew to a size of approx.
100 * 100 * 50 mm. They were briefly washed in mother liquor
supplemented with 10% sucrose, 10% xylitol and 15% ethylene
glycol prior to flash-cooling in liquid nitrogen. Nef–NI3-13 was
crystallized in a similar fashion, using a reservoir of 0.1 M Hepes
pH 7.0, 0.05 M sodium citrate, 15% isopropanol and 30%
glycerol as a cryoprotectant.
Diffraction data were collected on beamline X10SA of the Swiss
Light Source (SLS, Villigen, Switzerland) equipped with a MAR
225 CCD detector. The XDS package [56] was used for data
reduction and the structure of the Nef–NI1-2 complex was solved
by molecular replacement using the Nef-FynSH3 complex (PDB
entry 1EFN [36]) as a search model in PHASER [57]. The model
was refined to 2.0 A ˚ resolution by alternating cycles of manual
rebuilding in COOT [58] and minimization in REFMAC5 [59],
defining each of the four chains contained in the asymmetric unit
as a separate TLS body. The Nef–NI3-13 complex was solved by
molecular replacement with the refined structure of Nef–NI1-2
and the structure was refined against 3.45 A ˚ resolution data using
COOT and phenix.refine [60]. Due to the low resolution,
individual atomic displacement factor refinement was not
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refining the four chains as separate TLS groups. Data collection
and refinement statistics are summarized in Table 2. Molecular
diagrams were drawn using PyMOL (http://pymol.sourceforge.
net/).
Nuclear magnetic resonance spectroscopy
NMR spectroscopy experiments were carried out with a Varian
Inova 600 MHz spectrometer at 25uC in 5 mM Tris/HCL
(pH 8.0) buffer and 8% D2O. The 2D
1H/
15N HSQC spectra
were obtained by titrating 0.4–0.6 mM Nef with either NI1-2 or
the interacting fusion protein NI3-13 to a final concentration of
0.8 mM. Spectra were analyzed based on the resonance line
assignments of Nef, alleles BH10 and SF2 [61–63] using the
program AURELIA [64].
Cells and Reagents
293T and TZM cells were purchased from ATCC (Teddington,
UK). 293T, TZM (JC53BL), and TZM clone 13 cells (subcloned
for high expression of MHC-I by fluorescence-activated cell
sorting) were maintained in DMEM high medium (GIBCO)
supplemented with 10% fetal calf serum (Invitrogen), L-glutamine
and antibiotics (both from GIBCO) as described [8]. CHO
hCD4hCCR5 (stably expressing hCD4 and hCCR5) [65] cells
were cultured in RPMI 1640 medium supplemented accordingly.
Mammalian expression plasmids
The expression plasmid encoding wild-type HIV-1SF2 Nef as a
GFP fusion protein (from the pEGFP-N1 vector; Clontech) has
been described previously [65]. The proviral construct expressing
the nef gene of HIV-1 SF2 in the backbone of the HIV-1NL4-3
proviral clone has been described [8].
Immunofluorescence
To visualize the subcellular localization of Nef.GFP and HA-
tagged inhibitors, CHO hCD4hCCR5 cells were seeded onto glass
coverslips and transfected with corresponding expression plasmids.
36 hours later, cells were fixed with 4% paraformaldehyde/
phosphate-buffered saline (10 min at room temperature), permea-
bilized with 0.1% Tx-100, blocked for 1 h with 1% BSA in PBS,
and stained with HA-antibody (F7; Santa Cruz Biotechnology)
followed by appropriate fluorescent secondary antibody
(Alexa568, Molecular Probes). Following extensive washing, cells
were mounted with Histoprime (Linaris). Confocal microscopy
images were acquired with a LSM 510 confocal laser scanning
microscope (Zeiss). Final images were processed in PhotoshopCS2
(Adobe Systems).
Western Blotting
For Western blot analysis, post-nuclear supernatants were
boiled in SDS sample buffer, separated by 10% SDS-PAGE and
transferred to a nitrocellulose membrane. Protein detection was
performed following incubation with appropriate first and
secondary antibodies using the super signal pico detection kit
(Pierce) according to the manufacturer’s instructions.
Co-Immunoprecipitation
CHO hCD4hCCR5 cells were lysed in IP-lysis buffer (25 mM
Tris/HCl pH 7.4; 150 mM NaCl, 1 mM EDTA, 1% NP-40)
containing protease inhibitors. After removal of nuclei and cell
debris by centrifugation at 1.000 g for 10 min at 4uC, lysates were
incubated over night at 4uC with prepared GFP-protein A-
Sepharose beads (anti-GFP-antibodies incubated with protein A-
Sepharose (Pharmacia) for 2 h at room temperature in IP-buffer 1
(25 mM Tris/HCl pH 7.4; 150 mM NaCl, 1 mM EDTA, 0.5%
NP-40) and washed in IP-buffer 2 (25 mM Tris/HCl pH 7.4;
150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1% BSA). Samples
were pelleted, washed with IP-buffer 0 (25 mM Tris/HCl pH 7.4;
150 mM NaCl, 1 mM EDTA), and resuspended in sample-buffer.
After SDS-PAGE, western blotting with anti-HA-mAb was
performed.
Flow cytometry
24 h post-transfection surface molecules of Chinese hamster
ovary (CHO) hCD4hCCR5 or TZM clone 13 cells were stained,
respectively as reported previously [22,65]. Staining was per-
formed at 4uC for 30 min in fluorescence-activated cell sorting
(FACS) medium (3% FCS, 0.05% sodium azide in PBS) with anti-
hCD4-APC, anti-hCCR5-APC (both BD Pharmingen), anti-
CD71 (H68.4; Zymed Laboratories), and anti-MHC-I (W6/32-
FITC, Sigma-Aldrich) antibodies, respectively. For unconjugated
anti-CD71 mAb, secondary staining was performed with APC-
conjugated goat anti-mouse antibody (Jackson ImmunoResearch
Laboratories). Samples were analyzed by flow cytometry using a
FACSCalibur cytometer (Becton Dickinson).
Virus stocks and virion infectivity
Virus stocks were generated by transfection of proviral HIV
plasmids into 293T cells by the Ca-phosphate method. Two days
after transfection, culture supernatants were harvested. The CA
concentration of concentrated stocks was determined by CA
antigen enzyme-linked immunosorbent assay (ELISA) as described
[66]. Relative infectivity of HIV-1 particles was determined by CA
ELISA and a standardized 96-well TZM blue cell assay was
performed as described earlier [65]. Briefly, infections were carried
out in triplicates with 2 ng CA input virus. 36 hours post infection,
cells were fixed, stained for ß-galactosidase and the number of blue
cells was determined by microscopy.
Accession codes
Atomic coordinates and structure factors of the Nef-inhibitor
complexes were deposited in the Protein Data Bank with accession
codes 3REA for Nef–NI1-2 and 3REB for Nef–NI3-13,
respectively.
Supporting Information
Figure S1 Schematic display of the four generations of
inhibitor constructs used in cellular experiments. Do-
main boundaries, membrane targeting sites and sequence epitopes
attached for antibody recognition in vivo are indicated. Domain
boundaries for the human Hck SH3 domain are given according
to the UniProt database entry P08631-1, described as isoform 1 of
protein product p60-Hck. Residue numbering of human CD4 is
assigned according to UniProt protein entry P01730. All protein
products besides NI3-6 were targeted to cellular membranes either
by an N-terminal myristoylation motif or a C-terminal farnesyla-
tion signal, partly in combination with an additional palmitoyla-
tion signal for increased membrane association, which is
schematically indicated as carbon structure (zigzag lines).
(TIF)
Figure S2 Fluorescence spectroscopy analysis of the
binding interaction between Nef and NI3-3. (A) Emission
spectra of fluorescence-labeled NI3-3 Hexim1 alone and in
complex with Nef (1-210) indicate complex formation by an
increase and shift in fluorescence emission. (B) Analysis of an
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concentrations of Nef (1-210) indicated a dissociation constant Kd
of 37 nM. The relative fluorescence intensity was corrected for the
dilution effects.
(TIF)
Figure S3 Surface plasmon resonance measurements of
Nef binding to an inhibitor of the third generation. (A)
NefSF2 (45-210) was floated at four different concentrations (0.4 to
1.0 mM) over GST-NI3-9 which was immobilized on the chip
surface of the SPR biosensor. Following the association step Nef
protein was washed off after 400 s by Guanidine hydrochlorid. (B)
The concentration dependent analysis of the association and
dissociation reaction revealed a dissociation constant of 28 nM for
the Nef–GST-NI3-9 interaction.
(TIF)
Figure S4 Size exclusion chromatography of Nef and the
Nef–NI3-3 protein complex. While Nef (45-210) elutes at its
expected size of ,28 kDa as similarly observed before [53], the
Nef–NI3-3 complex elutes at a molecular weight of approximately
38 kDa. These observations suggest a heterodimeric but not a
heterotetrameric complex assembly, indicating that the gain in
affinity by the CD4 fraction in NI3-3 is achieved by the interaction
with the same Nef molecule. Note that the small portion of
oligomerized Nef in the void volume at 8.2 ml disappeared upon
addition of Nef inhibitor.
(TIF)
Figure S5 Expression and localization of NI3-1 to NI3-12
in human cells. (A) Localization of Nef and NIs in HeLa cells.
GFP or Nef.GFP was co-expressed with an empty control vector
or the indicated NIs and subjected to confocal microscopy analysis
following fixation and anti-HA immunostaining. Presented are
confocal sections of the middle of representative cells. (B) Western
blot analysis of lysates of the cells shown in (A) using an anti-HA
antibody for detection of the indicated NI proteins.
(TIF)
Figure S6 Structural details of the complex interface
between NefSF2 and NI1-2. (A) The central residues
Y89VSWSPDD of the mutated RT loop tightly interact with
helices a4 and a5 of Nef. Particularly the indol ring of W92NI1-2
performs multiple interactions with hydrophobic residues I91,
F94, W117 and I118 of Nef. (B) A polar cluster between S93 and
D95 of NI1-2 and K86 and D90 of Nef sustains the complex
binding. (C) Interactions of the newly identified N-terminal helix
(60–69) of Nef with its core domain structure. Tryptophane 61
undergoes tight interactions with L104, R110, I113 and L114 of
the Nef core domain structure, covering the distal hydrophobic
crevice of the a4 and a5 helices.
(TIF)
Figure S7 NMR titration series of NefSF2 (45-210, C59S,




15N labeled Nef in the initial, unperturbed state
(blue resonance signals), followed by addition of NI3-13 at a molar
ratio to Nef of 0.5 (orange lines) and 1.2 (red line).
(TIF)
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